Virtual Library
Start Your Search
H.J. Blaauwgeers
Author of
-
+
P1.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 233)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.04-039 - Ex-Vivo Artifacts and Histopathological Pitfalls in the Lung (ID 2602)
09:30 - 09:30 | Author(s): H.J. Blaauwgeers
- Abstract
Background:
Surgical and pathological handling of lung physically affects lung tissue. This leads to artifacts that alter the morphological appearance of pulmonary parenchyma.
Methods:
In this study four mechanisms of ex-vivo artifacts and corresponding diagnostic pitfalls are described and illustrated.
Results:
The four patterns of artifacts are: 1) Surgical collapse, due to the removal of air and blood from pulmonary resections; 2) Ex-vivo contraction of bronchial and bronchiolar smooth muscle; 3) Clamping edema of open lung biopsies, and 4) Spreading of tissue fragments and individual cells through a knife surface. Morphologic pitfalls include diagnostic patterns of adenocarcinoma, asthma, constrictive bronchiolitis, and lymphedema.
Conclusion:
Four patterns of pulmonary ex-vivo artifacts are important to recognize, in order to avoid morphologic misinterpretations, possibly improving reproducibility in histopathological diagnosis of lung cancer
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-083 - FGFR1, 2 and 3 Expression in Early Stage Non-Small-Cell Lung Cancer (ID 837)
09:30 - 09:30 | Author(s): H.J. Blaauwgeers
- Abstract
Background:
The aim of this study was to identify the protein expression levels of Fibroblast Growth Factor Receptors (FGFR) 1, 2 and 3 in early-stage non-small-cell lung carcinoma (NSCLC). Additionally, we performed a screen to define the frequency of FGFR3-TACC3 translocation and FGFR3 amplification.
Methods:
Archived tissue from 653 NSCLC samples (adenocarcinoma (AC), squamous cell carcinoma (SCC) and large cell carcinoma (LCC)) was analyzed with immunohistochemistry (IHC) for expression of FGFR1, 2 and 3. Expression levels of FGFR1, 2 and 3 were then correlated with clinicopathological features. The presence of FGFR3-TACC3 translocation was detected with RT-PCR and FGFR3 amplification was detected with FISH.
Results:
High protein expression of FGFR1, 2 and 3 was shown in 65 (10.5%), 78 (12.9%) and 20 (3.2%) of NSCLC tumor samples, respectively. Expression of FGFR1 was associated with light smoking (p = 0.007), AC (p < 0.000) and worse overall survival (p < 0.04). Expression of FGFR2 was associated with female sex (p < 0.001), younger age (p = 0.01) and AC (p < 0.000). Expression of FGFR3 was associated with male sex (p = 0.047), older patients (p = 0.01) and SCC (p < 0.000). FGFR3-TACC3 fusion was shown in 2.8% (6/210). In 45 FGFR3 IHC positive samples, two samples were FGFR3 amplified (4.4%) and one showed gain (2.2%).
Conclusion:
We show that FGFR1, 2 and 3 proteins are expressed in a significant number of NSCLC and identify some of the underlying molecular mechanisms. FGFR1 (but not FGFR2 and 3) protein overexpression is correlated with significant worse overall survival. FGFR1, 2 and 3 protein overexpression may become a new target of treatment in patients with NSCLC.
